Inoue T, Mi Z, Gillespie D G, Dubey R K, Jackson E K
Center for Clinical Pharmacology, Department of Pharmacology, University of Pittsburgh School of Medicine, Pennsylvania 15213-2582, USA.
J Pharmacol Exp Ther. 1999 Mar;288(3):1229-34.
In a previous study, we found that angiotensin (Ang) II enhances beta-adrenoceptor-induced cAMP production in cultured preglomerular microvascular smooth muscle cells (PMVSMCs) obtained from spontaneously hypertensive rats. The purpose of the present investigation was to identify the Ang receptor subtypes that mediate this effect. In our first study, we compared the ability of Ang II, Ang III, Ang (3-8), and Ang (1-7) to increase cAMP production in isoproterenol (1 microM)-treated PMVSMCs. Each peptide was tested at 0.1, 1, 10, 100, and 1000 nM. Both Ang II and Ang III increased intracellular (EC50s, 1 and 11 nM, respectively) and extracellular (EC50s, 2 and 14 nM, respectively) cAMP levels in a concentration-dependent fashion. In contrast, Ang (3-8) and Ang (1-7) did not enhance either intracellular or extracellular cAMP levels at any concentration tested. In our second study, we examined the ability of L 158809 [a selective Ang receptor subtype 1 (AT1) receptor antagonist] to inhibit Ang II (100 nM) and Ang III (100 nM) enhancement of isoproterenol (1 microM)-induced cAMP production in PMVSMCs. L 158809 (10 nM) abolished or nearly abolished (p <.001) Ang II and Ang III enhancement of isoproterenol-induced intracellular and extracellular cAMP levels. In contrast, PD 123319 (300 nM; a selective AT2 receptor antagonist) did not significantly alter Ang II enhancement of isoproterenol-induced intracellular or extracellular cAMP levels. We conclude that AT1 receptors, but not AT2, Ang (3-8), nor Ang (1-7) receptors mediate Ang II and Ang III enhancement of beta-adrenoceptor-induced cAMP production in cultured PMVSMCs.
在之前的一项研究中,我们发现血管紧张素(Ang)II可增强从自发性高血压大鼠获取的培养的肾小体前微血管平滑肌细胞(PMVSMCs)中β-肾上腺素能受体诱导的环磷酸腺苷(cAMP)生成。本研究的目的是确定介导此效应的Ang受体亚型。在我们的第一项研究中,我们比较了Ang II、Ang III、Ang(3-8)和Ang(1-7)在异丙肾上腺素(1微摩尔/升)处理的PMVSMCs中增加cAMP生成的能力。每种肽分别在0.1、1、10、100和1000纳摩尔浓度下进行测试。Ang II和Ang III均以浓度依赖性方式增加细胞内(半数有效浓度分别为1和11纳摩尔)和细胞外(半数有效浓度分别为2和14纳摩尔)cAMP水平。相比之下,在任何测试浓度下,Ang(3-8)和Ang(1-7)均未增强细胞内或细胞外cAMP水平。在我们的第二项研究中,我们检测了L 158809[一种选择性血管紧张素受体1(AT1)受体拮抗剂]抑制Ang II(100纳摩尔)和Ang III(100纳摩尔)增强异丙肾上腺素(1微摩尔/升)诱导的PMVSMCs中cAMP生成的能力。L 158809(10纳摩尔)消除或几乎消除了(p<0.001)Ang II和Ang III增强异丙肾上腺素诱导的细胞内和细胞外cAMP水平的作用。相比之下,PD 123319(300纳摩尔;一种选择性AT2受体拮抗剂)并未显著改变Ang II增强异丙肾上腺素诱导的细胞内或细胞外cAMP水平的作用。我们得出结论,在培养的PMVSMCs中,介导Ang II和Ang III增强β-肾上腺素能受体诱导的cAMP生成的是AT1受体,而非AT2、Ang(3-8)或Ang(1-7)受体。